Clinical trials: Cancer-Associated Thrombosis (CAT)
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 13 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Cancer, Pulmonary Embolism
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of…
- Conditions
- Cancer, Pulmonary Embolism, Thrombosis
- Trial name
- CATforCAT (NCT06386107)
- Testing
- Thrombin Generation Assay (TGA)
- Where
- 4 sites in France
- Volunteers
- 212 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- ASTER (NCT05171049)
- Testing
- Abelacimab, Apixaban
- Where
- 209 sites in United States, Australia and 19 more
- Volunteers
- 1,150 people
- Sponsor
- Anthos Therapeutics, Inc.
Venous Thromboembolism, Cancer
Cancer Associated Thrombosis : What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO
Venous thromboembolism is a common and fatal disease closely related to cancer. The therapeutic challenge is major due to the high risk of recurrent thromboembolism and bleeding in patients with cancer.
- Trial name
- NCT04846556
- Testing
- data collection
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Deep Vein Thrombosis, Pulmonary Embolism
Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology Patients
Prevention and Prophylaxis (Thromboprophylaxis - ACT) of Cancer Associated Thrombosis (CAT) in High Risk Oncology Patients: ACT4CAT.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Vena Cava Thrombosis, Iliac; Thrombosis
- Trial name
- NCT03909399
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Society of Medical Oncology
Venous Thromboembolism, Cancer
Statins to Prevent Cancer Associated Blood Clots
Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks.
- Conditions
- Venous Thromboembolism, Cancer, Cardiovascular Events
- Trial name
- STAT-CAT (NCT07303816)
- Testing
- Rosuvastatin
- Where
- 9 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Brigham and Women's Hospital
Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with…
- Trial name
- API-CAT (NCT03692065)
- Testing
- Apixaban 5 MG
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 1,766 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Deep Vein Thrombosis
Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder after myocardial infarction and stroke.
- Trial name
- STEP-CAT (NCT02752607)
- Where
- 7 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Dr. Vicky Tagalakis